Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.
Identifieur interne : 001285 ( PubMed/Corpus ); précédent : 001284; suivant : 001286Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.
Auteurs : Fang-Ying Liang ; Leng-Chieh Lin ; Tsung-Ho Ying ; Chen-Wen Yao ; Tswen-Kei Tang ; Yi-Wen Chen ; Ming-Hon HouSource :
- Journal of virological methods [ 1879-0984 ] ; 2013.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Viral (blood), Blotting, Western (methods), Clinical Laboratory Techniques (methods), Coronavirus Infections (diagnosis), Coronavirus OC43, Human (immunology), Female, Humans, Male, Middle Aged, Nucleocapsid Proteins (immunology), Recombinant Proteins (immunology), Young Adult.
- MESH :
- chemical , blood : Antibodies, Viral.
- diagnosis : Coronavirus Infections.
- immunology : Coronavirus OC43, Human, Nucleocapsid Proteins, Recombinant Proteins.
- methods : Blotting, Western, Clinical Laboratory Techniques.
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
Previous studies have reported that a prokaryotic-expressed recombinant nucleocapsid protein (NP) is a suitable reagent for the epidemiological screening of coronavirus infection. In this study, soluble recombinant human coronavirus OC43 (HCoV-OC43) NP was produced to examine the antigenicity of the HCoV-OC43 NP of betacoronavirus. Using the purified recombinant NP as an antigen, a polyclonal antibody from rabbit serum with specificity for HCoV-OC43 NP was generated; this antibody reacts specifically with HCoV-OC43 NP and does not cross-react with other human CoV NPs (including those of SARS-CoV and HCoV-229E) by Western blot. Sera from 26 young adults, 17 middle-aged and elderly patients with respiratory infection, and 15 cord blood samples were also tested. Strong reactivity to the NPs of HCoV-OC43 was observed in 96%, 82%, and 93% of the serum samples from the young adults, respiratory patients, and cord blood samples, respectively. To identify the immunoreactivities of the three structural regions of the NP that are recognised by the rabbit polyclonal antibody and human serum, the antigenicities of three protein fragments, including the N-terminal domain (aa 1-173), the central-linker region (aa 174-300), and the C-terminal domain (aa 301-448), were evaluated by Western blot. The rabbit polyclonal antibody demonstrated greater immunoreactivity to the central-linker region and the C-terminal domain than to the N-terminal domain. Three different patterns for the immunoreactivities of the three structural regions of HCoV-OC43 NP were observed in human serum, suggesting variability in the immune responses that occur during HCoV-OC43 infection in humans. The central-linker region of the NP appeared to be the most highly immunoreactive region for all three patterns observed. The goal of this study was to offer insight into the design of diagnostic tools for HCoV infection.
DOI: 10.1016/j.jviromet.2012.11.009
PubMed: 23174159
Links to Exploration step
pubmed:23174159Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.</title><author><name sortKey="Liang, Fang Ying" sort="Liang, Fang Ying" uniqKey="Liang F" first="Fang-Ying" last="Liang">Fang-Ying Liang</name><affiliation><nlm:affiliation>Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Leng Chieh" sort="Lin, Leng Chieh" uniqKey="Lin L" first="Leng-Chieh" last="Lin">Leng-Chieh Lin</name></author><author><name sortKey="Ying, Tsung Ho" sort="Ying, Tsung Ho" uniqKey="Ying T" first="Tsung-Ho" last="Ying">Tsung-Ho Ying</name></author><author><name sortKey="Yao, Chen Wen" sort="Yao, Chen Wen" uniqKey="Yao C" first="Chen-Wen" last="Yao">Chen-Wen Yao</name></author><author><name sortKey="Tang, Tswen Kei" sort="Tang, Tswen Kei" uniqKey="Tang T" first="Tswen-Kei" last="Tang">Tswen-Kei Tang</name></author><author><name sortKey="Chen, Yi Wen" sort="Chen, Yi Wen" uniqKey="Chen Y" first="Yi-Wen" last="Chen">Yi-Wen Chen</name></author><author><name sortKey="Hou, Ming Hon" sort="Hou, Ming Hon" uniqKey="Hou M" first="Ming-Hon" last="Hou">Ming-Hon Hou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23174159</idno><idno type="pmid">23174159</idno><idno type="doi">10.1016/j.jviromet.2012.11.009</idno><idno type="wicri:Area/PubMed/Corpus">001285</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001285</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.</title><author><name sortKey="Liang, Fang Ying" sort="Liang, Fang Ying" uniqKey="Liang F" first="Fang-Ying" last="Liang">Fang-Ying Liang</name><affiliation><nlm:affiliation>Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Leng Chieh" sort="Lin, Leng Chieh" uniqKey="Lin L" first="Leng-Chieh" last="Lin">Leng-Chieh Lin</name></author><author><name sortKey="Ying, Tsung Ho" sort="Ying, Tsung Ho" uniqKey="Ying T" first="Tsung-Ho" last="Ying">Tsung-Ho Ying</name></author><author><name sortKey="Yao, Chen Wen" sort="Yao, Chen Wen" uniqKey="Yao C" first="Chen-Wen" last="Yao">Chen-Wen Yao</name></author><author><name sortKey="Tang, Tswen Kei" sort="Tang, Tswen Kei" uniqKey="Tang T" first="Tswen-Kei" last="Tang">Tswen-Kei Tang</name></author><author><name sortKey="Chen, Yi Wen" sort="Chen, Yi Wen" uniqKey="Chen Y" first="Yi-Wen" last="Chen">Yi-Wen Chen</name></author><author><name sortKey="Hou, Ming Hon" sort="Hou, Ming Hon" uniqKey="Hou M" first="Ming-Hon" last="Hou">Ming-Hon Hou</name></author></analytic><series><title level="j">Journal of virological methods</title><idno type="eISSN">1879-0984</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Blotting, Western (methods)</term><term>Clinical Laboratory Techniques (methods)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus OC43, Human (immunology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nucleocapsid Proteins (immunology)</term><term>Recombinant Proteins (immunology)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus OC43, Human</term><term>Nucleocapsid Proteins</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Blotting, Western</term><term>Clinical Laboratory Techniques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous studies have reported that a prokaryotic-expressed recombinant nucleocapsid protein (NP) is a suitable reagent for the epidemiological screening of coronavirus infection. In this study, soluble recombinant human coronavirus OC43 (HCoV-OC43) NP was produced to examine the antigenicity of the HCoV-OC43 NP of betacoronavirus. Using the purified recombinant NP as an antigen, a polyclonal antibody from rabbit serum with specificity for HCoV-OC43 NP was generated; this antibody reacts specifically with HCoV-OC43 NP and does not cross-react with other human CoV NPs (including those of SARS-CoV and HCoV-229E) by Western blot. Sera from 26 young adults, 17 middle-aged and elderly patients with respiratory infection, and 15 cord blood samples were also tested. Strong reactivity to the NPs of HCoV-OC43 was observed in 96%, 82%, and 93% of the serum samples from the young adults, respiratory patients, and cord blood samples, respectively. To identify the immunoreactivities of the three structural regions of the NP that are recognised by the rabbit polyclonal antibody and human serum, the antigenicities of three protein fragments, including the N-terminal domain (aa 1-173), the central-linker region (aa 174-300), and the C-terminal domain (aa 301-448), were evaluated by Western blot. The rabbit polyclonal antibody demonstrated greater immunoreactivity to the central-linker region and the C-terminal domain than to the N-terminal domain. Three different patterns for the immunoreactivities of the three structural regions of HCoV-OC43 NP were observed in human serum, suggesting variability in the immune responses that occur during HCoV-OC43 infection in humans. The central-linker region of the NP appeared to be the most highly immunoreactive region for all three patterns observed. The goal of this study was to offer insight into the design of diagnostic tools for HCoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23174159</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>187</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J. Virol. Methods</ISOAbbreviation></Journal><ArticleTitle>Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.</ArticleTitle><Pagination><MedlinePgn>413-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jviromet.2012.11.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-0934(12)00389-8</ELocationID><Abstract><AbstractText>Previous studies have reported that a prokaryotic-expressed recombinant nucleocapsid protein (NP) is a suitable reagent for the epidemiological screening of coronavirus infection. In this study, soluble recombinant human coronavirus OC43 (HCoV-OC43) NP was produced to examine the antigenicity of the HCoV-OC43 NP of betacoronavirus. Using the purified recombinant NP as an antigen, a polyclonal antibody from rabbit serum with specificity for HCoV-OC43 NP was generated; this antibody reacts specifically with HCoV-OC43 NP and does not cross-react with other human CoV NPs (including those of SARS-CoV and HCoV-229E) by Western blot. Sera from 26 young adults, 17 middle-aged and elderly patients with respiratory infection, and 15 cord blood samples were also tested. Strong reactivity to the NPs of HCoV-OC43 was observed in 96%, 82%, and 93% of the serum samples from the young adults, respiratory patients, and cord blood samples, respectively. To identify the immunoreactivities of the three structural regions of the NP that are recognised by the rabbit polyclonal antibody and human serum, the antigenicities of three protein fragments, including the N-terminal domain (aa 1-173), the central-linker region (aa 174-300), and the C-terminal domain (aa 301-448), were evaluated by Western blot. The rabbit polyclonal antibody demonstrated greater immunoreactivity to the central-linker region and the C-terminal domain than to the N-terminal domain. Three different patterns for the immunoreactivities of the three structural regions of HCoV-OC43 NP were observed in human serum, suggesting variability in the immune responses that occur during HCoV-OC43 infection in humans. The central-linker region of the NP appeared to be the most highly immunoreactive region for all three patterns observed. The goal of this study was to offer insight into the design of diagnostic tools for HCoV infection.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Fang-Ying</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Leng-Chieh</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Tsung-Ho</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Chen-Wen</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Tswen-Kei</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Wen</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Ming-Hon</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028962" MajorTopicYN="N">Coronavirus OC43, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23174159</ArticleId><ArticleId IdType="pii">S0166-0934(12)00389-8</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2012.11.009</ArticleId><ArticleId IdType="pmc">PMC7112824</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Microbiol. 2004 Jul;42(7):2884-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15243033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biomed Sci. 2003 Nov-Dec;10(6 Pt 2):664-75</Citation><ArticleIdList><ArticleId IdType="pubmed">14631105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Microbiol Biotechnol. 2008 Oct;18(10):1717-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18955825</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2004 Mar 15;116(2):161-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14738983</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2000 Jul;31(1):96-100</Citation><ArticleIdList><ArticleId IdType="pubmed">10913403</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Jul;10(7):1213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15324540</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2005 Jan;12(1):135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15642998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Appl Bioinformatics. 2004;3(2-3):105-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15693736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2005 Jul;127(1):46-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15893565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Vet Sci. 2010 Jun;11(2):165-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20458159</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Jun;81(11):6079-88</Citation><ArticleIdList><ArticleId IdType="pubmed">17392374</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2006;336:163-75</Citation><ArticleIdList><ArticleId IdType="pubmed">16916262</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proteomics. 2005 Mar;5(4):925-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15759315</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18382647</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Virus Res. 1997;48:1-100</Citation><ArticleIdList><ArticleId IdType="pubmed">9233431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Epidemiol. 1971 Jul;94(1):43-9</Citation><ArticleIdList><ArticleId IdType="pubmed">5556222</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Microbiol Mol Biol Rev. 1998 Dec;62(4):1171-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9841669</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Aug;11(8):1225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16102311</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Diagn Microbiol Infect Dis. 2008 May;61(1):40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18191362</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Oct;74(19):8913-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10982334</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2007 Feb;139(2):175-80</Citation><ArticleIdList><ArticleId IdType="pubmed">17079026</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am Rev Respir Dis. 1974 Jun;109(6):621-4</Citation><ArticleIdList><ArticleId IdType="pubmed">4365165</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biomed Sci. 2004 Jan-Feb;11(1):117-26</Citation><ArticleIdList><ArticleId IdType="pubmed">14730215</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2005 Feb;75(2):181-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15602743</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2004 Nov 17;1:7</Citation><ArticleIdList><ArticleId IdType="pubmed">15548333</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Sci. 2009 Nov;18(11):2209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">19691129</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2010 Dec;17(12):2033-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20926700</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2008 Feb 29;331(1-2):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18191140</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Med. 2005;56:357-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15660517</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anal Chem. 2012 Aug 7;84(15):6391-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22712523</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2011 Oct;177(1):100-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21801752</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jul 1;66(Pt 7):815-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20606281</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2005 Oct;77(2):151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16121372</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Jun 15;191(12):2033-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15897988</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 2004 May 25;43(20):6059-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15147189</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Jan;79(2):884-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15613317</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Hosp Infect. 2002 May;51(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12009822</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Nov;10(11):1947-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15550204</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2003 Apr 15;36(8):985-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12684910</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Neurovirol. 2004 Apr;10(2):75-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15204926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 1995 Oct;55(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8537456</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Aug;78(16):8824-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15280490</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Aug;30(4):309-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15163419</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2006 Mar 1;42(5):634-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16447108</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2000 Jan;81(Pt 1):181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10640556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2005 Jun;76(2):137-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15834868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001285 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001285 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23174159
|texte= Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23174159" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |